Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Despite economic downturn, Senior Living Residences marches ahead

Despite economic downturn, Senior Living Residences marches ahead

Cognitive abilites other than memory may decline prior to clinical diagnosis in patients with Alzheimer's disease

Cognitive abilites other than memory may decline prior to clinical diagnosis in patients with Alzheimer's disease

Holistic care needed for people with Alzheimer's disease and dementia

Holistic care needed for people with Alzheimer's disease and dementia

The third “Exciting Biologies” meeting focuses on “Biology In Balance”

The third “Exciting Biologies” meeting focuses on “Biology In Balance”

Caring for Alzheimer's patients proves costly

Caring for Alzheimer's patients proves costly

Health policy research roundup

Health policy research roundup

Brookdale Senior Living enters asset purchase agreement with affiliates of Sunrise Senior Living

Brookdale Senior Living enters asset purchase agreement with affiliates of Sunrise Senior Living

AMHN to air new healthcare video segments of Saddle Ranch Productions on its network

AMHN to air new healthcare video segments of Saddle Ranch Productions on its network

Physician shortage affects older Americans' access to basic care

Physician shortage affects older Americans' access to basic care

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Applied Neurosolutions provides update regarding its blood-based Alzheimer’s test

Applied Neurosolutions provides update regarding its blood-based Alzheimer’s test

New findings highlight potential role of copper in Alzheimer's disease

New findings highlight potential role of copper in Alzheimer's disease

NIH awards a $2.2M grant to biochemist for a high-resolution electron microscope

NIH awards a $2.2M grant to biochemist for a high-resolution electron microscope

"Health This Week" television program shows how people are exploring to live better, healthier and longer lives

"Health This Week" television program shows how people are exploring to live better, healthier and longer lives

PP5 enzyme decrease in neurons can cause cell death in Alzheimer's disease patients

PP5 enzyme decrease in neurons can cause cell death in Alzheimer's disease patients

Study reveals large structural differences between natural prions and man-made synthetic analogs

Study reveals large structural differences between natural prions and man-made synthetic analogs

HDSA honors outstanding contributors against Huntington's Disease

HDSA honors outstanding contributors against Huntington's Disease

Research and development using stem cells from menstrual blood helps fight against breast cancer

Research and development using stem cells from menstrual blood helps fight against breast cancer

New findings on Alzheimer's disease suggest a possible way for treatment

New findings on Alzheimer's disease suggest a possible way for treatment

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.